Half-life of serum alpha-fetoprotein: An early prognostic index of recurrence and survival after hepatic resection for hepatocellular carcinoma

Annals of Surgery

Volumn 257, Issue 4, 2013, Pages 708-717

  Shim, Ju Hyun ^a   Han, Seungbong ^a   Lee, Young Joo ^a   Lee, Sung Gyu ^a   Kim, Kang Mo ^a   Lim, Young Suk ^a   Chung, Young Hwa ^a   Lee, Yung Sang ^a   Lee, Han Chu ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

alpha fetoprotein; half life; hepatocellular carcinoma; recurrence; survival

Indexed keywords

ALPHA FETOPROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CLINICAL INDICATOR; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER SURGERY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; HALF-LIFE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84875225769     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318273be70     Document Type: Article

References (28)

1. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022.
2. Fan ST, Mau Lo C, Poon RT, et al. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg. 2011;253:745-758.
3. Poon RT, Fan ST, Lo CM, et al. Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J Clin Oncol. 2000;18:1094-1101.
4. Tung-Ping Poon R, Fan ST,Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 2000;232:10-24.
5. Lim KC, Chow PK, Allen JC, et al.Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg. 2011;254:108-113.
6. Fong Y, Sun RL, Jarnagin W, et al. An analysis of 412 cases of hepatocellular carcinoma at aWestern center. Ann Surg. 1999;229:790-799; discussion 799-800.
7. Ikai I, Arii S, Kojiro M, et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer. 2004;101:796-802.
8. Toyoda H, Kumada T, Kaneoka Y, et al. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol. 2008;49:223-232.
9. Nanashima A, Taura N, Abo T, et al. Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient Ssurvival. Dig Dis Sci. 2011.
10. Nobuoka D, Kato Y, Gotohda N, et al. Postoperative serum alpha-fetoprotein level is a useful predictor of recurrence after hepatectomy for hepatocellular carcinoma. Oncol Rep. 2010;24:521-528.
11. Johnson PJ. The role of serumalpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis. 2001;5:145-159.
12. Lee SG, Hwang S. How I do it: assessment of hepatic functional reserve for indication of hepatic resection. J Hepatobiliary Pancreat Surg. 2005;12:38-43.
13. Marrero JA, Su GL,Wei W, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology. 2003;37:1114-1121.
14. Buamah PK, James OF, Skillen AW, et al. The value of tumour marker kinetics in the management of patients with primary hepatocellular carcinoma. J Surg Oncol. 1988;37:161-164.
15. Han SJ, Yoo S, Choi SH, et al. Actual half-life of alpha-fetoprotein as a prognostic tool in pediatric malignant tumors. Pediatr Surg Int. 1997;12:599-602.
16. Kohn J. The dynamics of serum alpha-fetoprotein in the course of testicular teratoma. Scand J Immunol. 1978;8:103-107.
17. Gitlin D, Boesman M. Serum alpha-fetoprotein, albumin, and gamma-Gglobulin in the human conceptus. J Clin Invest. 1966;45:1826-1838.
18. Liver (including intrahepatic bile ducts). In: Greene FL, Page DL, Fleming ID, et al., eds. AJCC Cancer staging manual: American Joint Committee on Cancer. 6th ed. New York/London: Springer; 2002:131-138.
19. Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243:229-235.
20. Vora SR, Zheng H, Stadler ZK, et al. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist. 2009;14:717-725.
21. RiazA,Ryu RK,Kulik LM, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol. 2009;27:5734-5742.
22. Chan SL, Mo FK, Johnson PJ, et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol. 2009;27:446-452.
23. Fujioka M, Nakashima Y, Nakashima O, et al. Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma. Hepatology. 2001;34:1128-1134.
24. Minagawa M, Makuuchi M, Takayama T, et al. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg. 2003;238:703-710.
25. Tateishi R, Shiina S, Yoshida H, et al. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology. 2006;44:1518-1527.
26. Schwartz M. A biomathematical approach to clinical tumor growth. Cancer. 1961;14:1272-1294.
27. Nakamura S, Nouso K, Sakaguchi K, et al. Sensitivity and specificity of desgamma- carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol. 2006;101:2038-2043.
28. Rahbari NN, Mehrabi A, Mollberg NM, et al. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg. 2011;253:453-469.